SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revance Therapeutics, Inc. – ‘10-Q’ for 9/30/15 – ‘R7’

On:  Tuesday, 11/10/15, at 5:11pm ET   ·   For:  9/30/15   ·   Accession #:  1479290-15-10   ·   File #:  1-36297

Previous ‘10-Q’:  ‘10-Q’ on 8/7/15 for 6/30/15   ·   Next:  ‘10-Q’ on 5/10/16 for 3/31/16   ·   Latest:  ‘10-Q’ on 11/8/23 for 9/30/23   ·   8 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/10/15  Revance Therapeutics, Inc.        10-Q        9/30/15   66:5.6M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    644K 
 2: EX-10.1     Material Contract                                   HTML     28K 
 3: EX-10.2     Material Contract                                   HTML     68K 
 4: EX-10.3     Material Contract                                   HTML     64K 
 5: EX-10.4     Material Contract                                   HTML     70K 
 6: EX-10.5     Material Contract                                   HTML     68K 
 7: EX-10.6     Material Contract                                   HTML     70K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
45: R1          Document and Entity Information                     HTML     39K 
35: R2          Condensed Consolidated Balance Sheets               HTML     99K 
43: R3          Condensed Consolidated Balance Sheets               HTML     31K 
                (Parenthetical)                                                  
48: R4          Condensed Consolidated Statement of Operations and  HTML     92K 
                Comprehensive Loss                                               
61: R5          Consolidated Statements of Cash Flows               HTML    171K 
37: R6          The Company and Basis of Presentation               HTML     36K 
42: R7          Summary of Significant Accounting Policies          HTML     39K 
32: R8          Medicis Settlement                                  HTML     30K 
25: R9          Cash Equivalents and Investments                    HTML     82K 
62: R10         Fair Value Measurements                             HTML     82K 
50: R11         Notes Payable and Financing Obligation              HTML     41K 
49: R12         Convertible Notes, Warrants, and Related            HTML     26K 
                Derivatives                                                      
54: R13         Interest Expense                                    HTML     62K 
55: R14         Commitments and Contingencies                       HTML     40K 
53: R15         Warrants                                            HTML     22K 
56: R16         Equity                                              HTML    105K 
44: R17         Net Loss per Share Attributable to Common           HTML     62K 
                Stockholders                                                     
46: R18         Subsequent Events                                   HTML     25K 
52: R19         Summary of Significant Accounting Policies          HTML     52K 
                (Policies)                                                       
66: R20         Cash Equivalents and Investments (Tables)           HTML     78K 
58: R21         Fair Value Measurements (Tables)                    HTML     79K 
39: R22         Notes Payable and Financing Obligation (Tables)     HTML     27K 
51: R23         Interest Expense (Tables)                           HTML     60K 
41: R24         Commitments and Contingencies (Tables)              HTML     28K 
22: R25         Equity (Tables)                                     HTML     92K 
59: R26         Net Loss per Share Attributable to Common           HTML     62K 
                Stockholders (Tables)                                            
63: R27         The Company and Basis of Presentation - Additional  HTML     60K 
                Information (Detail)                                             
28: R28         Medicis Settlement - Additional Information         HTML     49K 
                (Detail)                                                         
27: R29         Cash Equivalents and Investments (Details)          HTML     44K 
30: R30         Fair Value Measurements - Schedule of Fair Value    HTML     53K 
                of Financial Instruments (Detail)                                
31: R31         Fair Value Measurements - Summary of Changes in     HTML     27K 
                Fair Value of Financial Instruments (Detail)                     
33: R32         Notes Payable and Financing Obligation - Hercules   HTML     54K 
                Notes Payable (Detail)                                           
21: R33         Notes Payable and Financing Obligation - Essex      HTML     58K 
                Capital Notes (Detail)                                           
57: R34         Notes Payable and Financing Obligation - Summary    HTML     29K 
                of Aggregate Total Future Minimum Lease Payments                 
                under the Financing Obligation (Detail)                          
38: R35         Convertible Notes, Warrants, and Related            HTML     61K 
                Derivatives - Additional Information (Detail)                    
40: R36         Interest Expense - Summary of Interest Expense by   HTML     42K 
                Cash and Non-Cash Components (Detail)                            
24: R37         Commitments and Contingencies - Additional          HTML     34K 
                Information (Detail)                                             
65: R38         Commitments and Contingencies - Schedule of Future  HTML     38K 
                Minimum Lease Payments under Non-Cancelable                      
                Operating Leases (Detail)                                        
18: R39         Warrants - Additional Information (Detail)          HTML     28K 
34: R40         Equity - Additional Information (Detail)            HTML     69K 
60: R41         Equity - Fair Value Assumptions (Details)           HTML     44K 
23: R42         Equity - Schedule of Stock-based Compensation       HTML     30K 
                Expense (Details)                                                
26: R43         Equity - Schedule of Accumulated Other              HTML     33K 
                Comprehensive Income (Details)                                   
29: R44         Net Loss per Share Attributable to Common           HTML     45K 
                Stockholders - Schedule of Computation of Basic                  
                and Diluted Net Income (Loss) Per Share                          
                Attributable to Common Stockholders (Detail)                     
36: R45         Net Loss per Share Attributable to Common           HTML     34K 
                Stockholders - Summary of Common Stock Equivalents               
                Excluded from Computation of Diluted Net Income                  
                (Loss) Per Share (Detail)                                        
20: R46         Subsequent Events (Details)                         HTML     46K 
64: XML         IDEA XML File -- Filing Summary                      XML    106K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX     58K 
12: EX-101.INS  XBRL Instance -- rvnc-20150930                       XML   1.30M 
14: EX-101.CAL  XBRL Calculations -- rvnc-20150930_cal               XML    173K 
15: EX-101.DEF  XBRL Definitions -- rvnc-20150930_def                XML    354K 
16: EX-101.LAB  XBRL Labels -- rvnc-20150930_lab                     XML   1.10M 
17: EX-101.PRE  XBRL Presentations -- rvnc-20150930_pre              XML    636K 
13: EX-101.SCH  XBRL Schema -- rvnc-20150930                         XSD    123K 
47: ZIP         XBRL Zipped Folder -- 0001479290-15-000010-xbrl      Zip    149K 


‘R7’   —   Summary of Significant Accounting Policies


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.3.0.814
Summary of Significant Accounting Policies
9 Months Ended
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies

Significant accounting policies are described in Note 2 to the consolidated financial statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. There have been no changes to the Company’s significant accounting policies during the three and nine months ended September 30, 2015, except as described below.

Use of Estimates
The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investment securities with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents may include cash on deposit, money market funds, and debt securities.
Investments
Short-term investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. All of its investments are classified as available-for-sale and carried at fair value, with the change in unrealized gains and losses reported as a separate component of other comprehensive income (loss) on the Condensed Consolidated Statements of Operations and Comprehensive Loss and accumulated as a separate component of stockholders' equity on the Condensed Consolidated Balance Sheets. Interest income, net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of investments, if any. The cost of securities sold is based on the specific-identification method. The Company monitors its investment portfolio for potential impairment on a quarterly basis. If the carrying amount of an investment in debt securities exceeds its fair value and the decline in value is determined to be other-than-temporary, the carrying amount of the security is reduced to fair value and a loss is recognized in operating results for the amount of such decline. In order to determine whether a decline in value is other-than-temporary, the Company evaluates, among other factors, the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, and its intent and ability to hold the security to maturity or forecasted recovery. The Company mitigates its credit risk by investing in money market funds and U.S. government agency obligations which limits the amount of investment exposure as to credit quality and maturity.
Fair Value of Financial Instruments
The Company uses fair value measurements to record fair value adjustments to certain financial and non-financial assets and liabilities to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
The three levels of inputs that may be used to measure fair value are as follows:
 
 
Level 1
Observable inputs, such as quoted prices in active markets for identical assets or liabilities.
 
 
 
 
 
Level 2
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
 
 
 
 
Level 3
Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.


Accounting Pronouncements
In August 2014, the FASB issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), which will require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year of the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The guidance defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. The guidance is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Company’s financial statements.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
12/15/16
Filed on:11/10/15
For Period end:9/30/15
12/31/1410-K,  ARS
 List all Filings 


8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Revance Therapeutics, Inc.        S-8         2/29/24    4:123K
 2/28/24  Revance Therapeutics, Inc.        10-K       12/31/23  110:12M
 2/28/23  Revance Therapeutics, Inc.        S-8         2/28/23    5:192K
 2/28/23  Revance Therapeutics, Inc.        10-K       12/31/22  109:14M
 2/28/22  Revance Therapeutics, Inc.        S-8         2/28/22    5:197K
 2/28/22  Revance Therapeutics, Inc.        10-K       12/31/21  106:12M
 2/25/21  Revance Therapeutics, Inc.        10-K       12/31/20  109:12M
 1/29/21  Revance Therapeutics, Inc.        S-8         1/29/21    3:137K
Top
Filing Submission 0001479290-15-000010   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 10:56:03.1pm ET